The solutions to emerging disease problems involve politics and policy issues, as well as solid science. The National Academy of Sciences' Institute of Medicine (IOM), whose mission is to "improve the health of people of the nation and the world," draws upon the expertise of elected members as well as others in the United States and other nations to make policy recommendations. Groups convene to debate contentious issues and publish evidence-based reports with recommendations to government, academia, industry, and the public.

Evidence-based reports are the foundation upon which policy can be built. In this last decade, IOM has produced several documents that have focused on emerging infections and provided a springboard for policy on a local, nationwide, and international scale. The U.S. Capacity to Address Tropical Infectious Disease Problems (1987) (1) concluded that U.S. capacity was barely adequate and that improvement in policies and modest additional funding could make a substantially stronger contribution to the field. Required efforts included sustained support for basic and applied research; accelerated development and testing of new preventive, therapeutic, and diagnostic technologies; sustainable career structures for tropical disease professionals; increased capacity to train U.S. tropical disease professionals and those from developing countries in research and public health service; development of disease surveillance capabilities; strengthened institutional capabilities in developing countries; and flexible, responsive administration of programs.

The Future of Public Health (1988) (2) report made three basic recommendations regarding the mission of public health and defined its core functions to be assessment, policy development, and assurance. It also included guidance for the government's role in fulfilling the public health mission and the responsibilities unique to each level of government. The report has been a useful blueprint for the past decade.

Emerging Infections: Microbial Threats to Health in the United States (1992) (3) identified significant emerging infectious diseases, determined what might be done to deal with them, and recommended how similar future threats might be confronted to lessen their impact on public health. The document focused on factors contributing to disease emergence, not the diseases themselves: human demographics and behavior, technology and industry, economic development and land use, international travel and commerce, microbial adaptation and change, and the breakdown of public health measures.

Sexually Transmitted Diseases: The Hidden Epidemic (1997) (4) focused on the need for a new social norm of healthy sexual behavior. The small investment in prevention efforts was contrasted with the very high costs of care for treating sexually transmitted diseases (STDs) (Figure 1). The report also examined the obstacles and opportunities presented by managed care. Limitations include the low priority for STD prevention, emphasis on short-term cost savings,
varying technical capabilities for diagnosis and
treatment, and patient concerns about confiden-
tiality and treatment of partners not enrolled in
the same health plan. Lastly, opportunities for
training and continuing education in STD control
and prevention are not built into most managed
care settings. The report called for several steps
including a national campaign to heighten
awareness of the human and financial costs of
STDs and to promote the use of social marketing
techniques for their prevention. A recent
innovative informational campaign used a niche
approach and a social marketing strategy with
the spot video Hittin’ the Skins and the public
service announcement Knockin’ Boots (D.
Futterman, pers. comm.), geared toward
alerting 16- to 21-year-olds of the need for HIV
testing.

Many related activities, in addition to the
IOM reports, have underscored the danger of
emerging infectious diseases and reiterated the
warnings about the overall erosion of the U.S.
public health system during the 1990s. The
reports also provided specific, detailed recom-
mendations for action by individual agencies. In
1994, the Centers for Disease Control and
Prevention (CDC) published Addressing Emerg-
ing Infectious Disease Threats: A Prevention
Strategy for the United States. In the same year,
the U.S. National Science and Technology
Council’s Committee on International Science,
Engineering, and Technology (an interagency
working group) was convened to consider the
global threat of emerging and reemerging
infectious diseases and in 1995 published the
report Infectious Disease—A Global Health
Threat. In 1995, the National Security Council
asked the federal government to examine its
preparedness to respond to global epidemics.
In 1995, the Centers for Disease Control and
Prevention (CDC) published Addressing Emerg-
ing Infectious Disease Threats: A Prevention
Strategy for the United States. In the same year,
the U.S. National Science and Technology
Council’s Committee on International Science,
Engineering, and Technology (an interagency
working group) was convened to consider the
global threat of emerging and reemerging
infectious diseases and in 1995 published the
report Infectious Disease—A Global Health
Threat. In 1995, the National Security Council
asked the federal government to examine its
preparedness to respond to global epidemics.
In 1995, the Food Safety and Inspection
Service, CDC, and the Food and Drug
Administration (FDA) developed the Sentinel
Site Study, which evolved into FoodNet and
now includes collection of more precise
information on the incidence of foodborne
disease in the United States. In 1996, President
Clinton’s administration set out a new policy to
establish a worldwide infectious disease
surveillance and response system and expand
certain federal agency mandates to better
protect American citizens.

In the 1996 NIAID Research Agenda for
Emerging Infectious Diseases, the National
Institutes of Health described research and
training issues relevant to the national strategy
for confronting the threat of emerging and
reemerging infections and related its approach to
addressing these issues.

In 1996, the Department of State established
an Emerging Infectious Diseases and HIV/AIDS
Program to serve as a focal point for the
development and implementation of U.S. foreign
policy objectives to improve the health of U.S.
citizens and to stem the spread of infectious
diseases worldwide through various interna-
tional bilateral and multilateral negotiations.
This program has received $50 million in
funding. Other government agencies, including
FDA, U.S. Agency for International Develop-
ment, Department of Defense, National Oceanic
and Atmospheric Administration, National Aero-
nautics and Space Administration, and U.S.
Department of Agriculture, have also examined
the issue of U.S. vulnerability to epidemics and
resurgence of infectious disease threats.

The IOM’s Forum on Emerging Infections is
the most recent activity within the National
Academy of Sciences to keep sustained attention
on these issues. The forum was established in
1996 to provide a structured opportunity for
discussion and to scrutinize critical, and possibly
contentious, scientific and policy issues related to
research on and the prevention, detection, and
management of new and reemerging infections.
The forum has organized a series of workshops to
be conducted over 30 months. Workshop topics
include costs of infectious diseases, surveillance,
antimicrobial resistance, effects of health-care
restructuring on public health and basic research
related to infectious diseases, capacity for
emergency response to emerging and reemerging
infectious diseases, education and training needs,
predicting the future, and behavioral interventions.

Orphans and Incentives (5), a 1998 report, is
the first publication of the forum; it focused on
constraints that have left an undefined group of
“urgently needed medical products in an
orphaned condition which demands special
attention.” The authors examined these products
across the product cycle and then classified them
into categories for which incentives might be
developed to bolster the competitiveness of such
products in industrial portfolios.

The 1998 report Antimicrobial Resistance (6),
the second publication of the forum, examined
increases in the number of pathogens, multidrug-
resistant strains, compromised persons (including HIV-infected patients), deaths from infection with resistant organisms, speed of the global spread, and costs of health care. The report also examined decreases in the antimicrobial armamentarium, amount of research and development expended when resistance was not seen as a major threat, and funding for public health infrastructure and addressed the following topics: expansion, coordination, and improvement of the diverse elements of surveillance; need for relatively small but thoughtful investments in research, clinical management and practice, and policy; use of antibiotics in food production; ways to prolong the effectiveness of existing antibiotics; basic research and incentives for new antibiotics; and legal and regulatory mechanisms in key areas of need.

A soon-to-be-published report on a March 1998 workshop on managed care will examine the implications of managed care systems on emerging infections by reviewing basic and clinical research, clinical practice guidelines, surveillance and monitoring, prevention, education and outreach, and product development.

These reports and events have examined research on emerging infectious diseases and crafted a series of policy recommendations. They put forth a rationale for why the United States should invest in global health. The 1997 report, entitled America’s Vital Interest in Global Health (7), provided a new framework for thinking about the benefits to the United States, as well as to the rest of the world, of our increased participation. The movement of two million people each day across national borders and the growth of international commerce are inevitably associated with transfers of health risks (e.g., infectious diseases, contaminated food, terrorism, and legal or banned toxic substances). U.S. commitment to global health serves to protect our people, enhance our economy, and advance our international interests. Moreover, governments are no longer the sole agents in the global health arena (Figure 2).

The United States can contribute not only with funding, but also with the scientific and technical expertise in its health sector. The United States should lead from its strengths (medical science and technology) in the areas of research and development, surveillance, education and training, global partnerships, and coordination and leadership. In this way, the United States “can do well by doing good.”

Figure 2. The growing role of the World Bank in health (7).

Acknowledgments

The author thanks Carol Bock for her assistance in preparing this manuscript and Jonathan Davis for collecting background materials.

References


